Core Insights - Aclaris Therapeutics reported a quarterly loss of $0.12 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of +7.69% [1] - The company generated revenues of $3.3 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 107.75%, although this is a decline from $4.35 million in the same quarter last year [2] - Aclaris shares have underperformed, losing about 8.9% since the beginning of the year, compared to a 15.6% gain in the S&P 500 [3] Financial Performance - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $1.57 million, and for the current fiscal year, it is -$0.51 on revenues of $6.39 million [7] Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aclaris' stock performance [5][6]

Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +88.89%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.78 per share when it actually produced a loss of $0.41, delivering a surpr ...

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this drug developer would post earnings of $0.23 per share when it actually produced earnings of $0.29, delivering a surprise of +26.09%.Over the last four quarters ...

Core Insights - Neurocrine Biosciences reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.58 per share, and showing an increase from $1.24 per share a year ago, resulting in an earnings surprise of +29.11% [1] - The company achieved revenues of $794.9 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.73% and up from $622.1 million year-over-year [2] - Neurocrine shares have increased approximately 9.1% year-to-date, while the S&P 500 has gained 16.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.71 on revenues of $785.17 million, and for the current fiscal year, it is $4.49 on revenues of $2.79 billion [7] - The estimate revisions trend for Neurocrine was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Neurocrine belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Amneal Pharmaceuticals, another company in the same industry, is expected to report quarterly earnings of $0.13 per share, reflecting a year-over-year decline of -18.8%, with revenues projected at $773.6 million, up 10.1% from the previous year [9][10]

Core Insights - NewAmsterdam Pharma Company N.V. (NAMS) shares increased by 5.9% to $32.48, with a notable trading volume, reflecting a 13.6% gain over the past four weeks [1][2] Company Overview - The rise in NAMS stock price is linked to investor optimism surrounding its investigational candidate, obicetrapib, which is being evaluated for lowering LDL-C in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia across three pivotal late-stage studies [2] Financial Expectations - The company is projected to report a quarterly loss of $0.41 per share, marking a year-over-year decline of 127.8%, with expected revenues of $2.35 million, down 91.9% from the previous year [3] - The consensus EPS estimate for NAMS has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - NAMS operates within the Zacks Medical - Drugs industry, where another company, Stevanato Group (STVN), experienced a 5.6% decline in stock price, closing at $24.53, despite a 7.6% return over the past month [4] - Stevanato's consensus EPS estimate has remained stable at $0.15, reflecting a year-over-year increase of 15.4%, and it holds a Zacks Rank of 2 (Buy) [5]

分组1 - Lyra Therapeutics reported a quarterly loss of $5.51 per share, which was better than the Zacks Consensus Estimate of a loss of $5.79, and an improvement from a loss of $14.5 per share a year ago, resulting in an earnings surprise of +4.84% [1] - The company posted revenues of $0.18 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 26.21%, although this was a decline from year-ago revenues of $0.6 million [2] - Lyra Therapeutics shares have declined approximately 35.4% year-to-date, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for Lyra Therapeutics is mixed, with the current consensus EPS estimate for the upcoming quarter at -$6.52 on revenues of $0.15 million, and -$2.02 on revenues of $0.45 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Company Performance - Karyopharm Therapeutics reported a quarterly loss of $4.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.8, and compared to a loss of $3 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $37.93 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 5.37%, and down from $42.79 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Karyopharm shares have lost approximately 61.1% since the beginning of the year, contrasting with the S&P 500's gain of 8.6%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$3.58 on revenues of $39.87 million, and for the current fiscal year, it is -$12.57 on revenues of $149.93 million [7] Industry Context - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong position within the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Karyopharm's stock performance [5]

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +22.22% [1] - The company posted revenues of $10 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.62%, and a decline from year-ago revenues of $20.1 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Movement and Outlook - Shares of Aquestive Therapeutics have increased by approximately 9.6% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $12.33 million, and for the current fiscal year, it is -$0.72 on revenues of $45.27 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Company Performance - Akebia Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.04 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $62.47 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 33.50%, compared to year-ago revenues of $43.65 million [2] - Over the last four quarters, Akebia has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Akebia Therapeutics shares have increased approximately 99.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $46.52 million, and for the current fiscal year, it is -$0.05 on revenues of $199.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Akebia belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can materially impact stock performance [5][8]

Group 1 - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.56 per share a year ago, resulting in an earnings surprise of +17.24% [1] - The company achieved revenues of $146.56 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.30%, and up from $122.71 million in the same quarter last year [2] - Catalyst has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%, suggesting a slight underperformance relative to the broader market [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The Zacks Rank for Catalyst is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $138.29 million, while for the current fiscal year, the estimate is $2.25 on revenues of $559.96 million [7] - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]